Partnering with Vespa Capital marks an exciting step in FibroFind’s growth journey. We are already seeing strong international demand for our platform, and this investment will allow us to scale further.

Jelena Mann, CEO at FibroFind

Business Profile

FibroFind is a pioneering life sciences business specialising in advanced human ex vivo tissue models for pre-clinical drug development.

Founded by a team of world-leading scientists from Newcastle University, the company delivers cutting-edge solutions that enhance the predictive accuracy of pre-clinical drug testing across a range of organs, including the liver, kidney, and lung.

FibroFind’s proprietary technology enables pharmaceutical companies to improve the efficiency and translational relevance of their research, ultimately accelerating the development of safe and effective therapies. The business operates at the forefront of the growing demand for alternatives to animal models, offering scalable and ethically sourced human tissue platforms.

Vespa Capital is supporting FibroFind’s continued innovation and commercial growth, helping the business capitalise on increasing global interest in predictive human models for drug discovery.

Visit FibroFind

Investment Date: April 2025
Biopharma Clients: 65+
Founded: 2019
Sector: Life Sciences

Key Strengths

Vespa Capital invested in FibroFind in April 2025, attracted by its cutting-edge solutions that enhance the predictive accuracy of pre-clinical drug development.

Proprietary ex vivo technology platform delivering highly predictive insights across both healthy and diseased tissue in key organs, offering a superior alternative to traditional pre-clinical models
Directly addresses a growing industry need for more accurate, human-relevant platforms in drug discovery, reducing reliance on animal testing and improving translational outcomes.
Founded by internationally recognised fibrosis researchers from Newcastle University, ensuring deep scientific credibility

Rapidly expanding customer base including global pharmaceutical and biotech companies, with strong reoccurring revenues and long-term client relationships
Compelling value proposition for clients who receive an increased level of predictability around their clinical outcomes, ultimately enhancing their success rates and materially reducing overall drug development costs

What our clients say

Partnering with Vespa Capital marks an exciting step in FibroFind’s growth journey. As regulatory and industry momentum continues to shift towards human-relevant models, we are ideally placed to help our clients make faster, more confident decisions with better data.